Why Innate Pharma’s 76-patient IPH4502 milestone is only half the Nectin-4 story
Innate Pharma completed IPH4502 dose-escalation enrollment, putting safety, response durability and dose selection at the center of a year-end readout.
Pharma & Biotech
Pharma & Biotech
Mabwell’s Nectin-4 ADC shows cervical cancer activity, but can Phase 3 confirm survival benefit?
Updated 9MW2821 data support Nectin-4 as a target in cervical cancer, but Mabwell must prove that early response and survival signals outperform established ADC and immunotherapy options.
Pharma & Biotech
Aktis Oncology raises $318m IPO: What this means for alpha radiotherapy biotech bets
Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.